{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:57:36Z","timestamp":1792292256252,"version":"4.4.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Concurrent chemoradiotherapy (CCRT) is the standard curative treatment option for nonmetastatic anal squamous cell carcinoma (SCC). Intensity modulated radiotherapy (IMRT) can reduce doses delivered to bowel and skin and reduce toxicities associated with conventional fields. Here, we present our institutional data on dosimetry, toxicity, and clinical outcomes with IMRT for anal cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and Methods:<\/jats:title>\n                    <jats:p>We analyzed 23 patients of anal SCC treated with curative-intent CCRT\/radiation therapy alone, utilizing IMRT, between August 2011 and December 2016. The standard prescription dose was 54 Gy\/27Fr\/5.5 weeks, delivered in two phases, and concurrent chemotherapy with 5-fluorouracil and mitomycin-C. Acute and late toxicities and dosimetric data were compiled and analyzed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>The median age was 65 years. Fourteen (60.7%) patients had Stage IIIC disease. Eighteen patients received concurrent chemotherapy. No patient had any treatment breaks. Grade 3 acute perianal dermatitis was recorded in 11 (47.8%) patients. Proctitis, diarrhea, and cystitis were limited to Grade 1 in 73.9%, 47.8%, and 8.6% patients, respectively. The only late Grade 2+ toxicities were gastrointestinal toxicities in 4 (17.4%) patients. Twenty (87%) patients had complete response at 6 months. The 3-year local control, nodal control, and distant metastases-free survival were 85.9%, 86.6%, 84.7%, respectively, with 3-year disease-free survival and overall survival of 63.4% and 81%, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In this report on IMRT in anal cancer from India, treatment was well tolerated with lower acute toxicity than reported in other prospective studies. Long-term results are at par with other published studies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.4103\/jcrt.jcrt_212_19","type":"journal-article","created":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T07:23:06Z","timestamp":1631776986000},"page":"975-981","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":3,"title":["Intensity modulated radiotherapy in anal canal squamous cell carcinoma"],"prefix":"10.4103","volume":"17","author":[{"given":"Avipsa","family":"Das","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moses","family":"Arunsingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tapesh","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S Sriram","family":"Prasath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arun","family":"Balakrishnan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Indranil","family":"Mallick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-24-20241021","first-page":"509","article-title":"Treatment of epidermoid carcinoma of the anal canal","volume":"161","author":"Greenall","year":"1985","journal-title":"Surg Gynecol Obstet"},{"key":"R2-24-20241021","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1002\/1097-0142(19830515)51:10<1826::AID-CNCR2820511012>3.0.CO;2-L","article-title":"Combined preoperative radiation and chemotherapy for squamous cell carcinoma of the anal canal","volume":"51","author":"Nigro","year":"1983","journal-title":"Cancer"},{"key":"R3-24-20241021","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1002\/1097-0142(19841115)54:10<2062::AID-CNCR2820541004>3.0.CO;2-T","article-title":"Results and toxicity of the treatment of anal canal carcinoma by radiation therapy or radiation therapy and chemotherapy","volume":"54","author":"Cummings","year":"1984","journal-title":"Cancer"},{"key":"R4-24-20241021","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0360-3016(97)00329-5","article-title":"Time-dose considerations in the treatment of anal cancer","volume":"39","author":"Constantinou","year":"1997","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R5-24-20241021","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/S0360-3016(01)01510-3","article-title":"The impact of gap duration on local control in anal canal carcinoma treated by split-course radiotherapy and concomitant chemotherapy","volume":"50","author":"Weber","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R6-24-20241021","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1200\/JCO.1996.14.9.2527","article-title":"Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: Results of a phase III randomized intergroup study","volume":"14","author":"Flam","year":"1996","journal-title":"J Clin Oncol"},{"key":"R7-24-20241021","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1200\/JCO.1997.15.5.2040","article-title":"Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups","volume":"15","author":"Bartelink","year":"1997","journal-title":"J Clin Oncol"},{"key":"R9-24-20241021","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1001\/jama.299.16.1914","article-title":"Fluorouracil, mitomycin, and radiotherapy vs fluorouracil, cisplatin, and radiotherapy for carcinoma of the anal canal: A randomized controlled trial","volume":"299","author":"Ajani","year":"2008","journal-title":"JAMA"},{"key":"R10-24-20241021","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/sj.bjc.6605605","article-title":"Chemoradiation for the treatment of epidermoid anal cancer: 13-year follow-up of the first randomised UKCCCR anal cancer trial (ACT I)","volume":"102","author":"Northover","year":"2010","journal-title":"Br J Cancer"},{"key":"R11-24-20241021","doi-asserted-by":"crossref","first-page":"4344","DOI":"10.1200\/JCO.2012.43.8085","article-title":"Long-term update of US GI intergroup RTOG 98-11 phase III trial for anal carcinoma: Survival, relapse, and colostomy failure with concurrent chemoradiation involving fluorouracil\/mitomycin versus fluorouracil\/cisplatin","volume":"30","author":"Gunderson","year":"2012","journal-title":"J Clin Oncol"},{"key":"R12-24-20241021","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.ijrobp.2005.05.052","article-title":"Organ sparing by conformal avoidance intensity-modulated radiation therapy for anal cancer: Dosimetric evaluation of coverage of pelvis and inguinal\/femoral nodes","volume":"63","author":"Chen","year":"2005","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R13-24-20241021","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/1748-717X-2-41","article-title":"Optimal organ-sparing intensity-modulated radiation therapy (IMRT) regimen for the treatment of locally advanced anal canal carcinoma: A comparison of conventional and IMRT plans","volume":"2","author":"Menkarios","year":"2007","journal-title":"Radiat Oncol"},{"key":"R14-24-20241021","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.1200\/JCO.2007.12.0170","article-title":"Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: A multicenter experience","volume":"25","author":"Salama","year":"2007","journal-title":"J Clin Oncol"},{"key":"R15-24-20241021","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/ajco.12768","article-title":"Image-guided IMRT with simultaneous integrated boost as per RTOG 0529 for the treatment of anal cancer","volume":"14","author":"Arcadipane","year":"2018","journal-title":"Asia Pac J Clin Oncol"},{"key":"R16-24-20241021","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s00432-018-2608-6","article-title":"Modern intensity modulated radiotherapy with image guidance allows low toxicity rates and good local control in chemoradiotherapy for anal cancer patients","volume":"144","author":"De Bari","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"R17-24-20241021","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ijrobp.2012.09.023","article-title":"RTOG 0529: A phase 2 evaluation of dose-painted intensity modulated radiation therapy in combination with 5-fluorouracil and mitomycin-C for the reduction of acute morbidity in carcinoma of the anal canal","volume":"86","author":"Kachnic","year":"2013","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"R18-24-20241021","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.radonc.2014.04.013","article-title":"Anal cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"111","author":"Glynne-Jones","year":"2014","journal-title":"Radiother Oncol"},{"key":"R19-24-20241021","first-page":"70","article-title":"Comparison of bone marrow sparing intensity modulated radiotherapy (IMRT) and three-dimensional conformal radiotherapy (3DCRT) in carcinoma of anal canal: A prospective study","volume":"4","author":"Rattan","year":"2016","journal-title":"Ann Transl Med"},{"key":"R21-24-20241021","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.adro.2017.01.009","article-title":"Long-term outcomes and toxicities of a large cohort of anal cancer patients treated with dose-painted IMRT per RTOG 0529","volume":"2","author":"Mitra","year":"2017","journal-title":"Adv Radiat Oncol"},{"key":"R22-24-20241021","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0959-8049(02)00377-5","article-title":"Shortened irradiation scheme, continuous infusion of 5-fluorouracil and fractionation of mitomycin C in locally advanced anal carcinomas. Results of a phase II study of the European organization for research and treatment of cancer. Radiotherapy and gastrointestinal cooperative groups","volume":"39","author":"Bosset","year":"2003","journal-title":"Eur J Cancer"},{"key":"R23-24-20241021","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.radonc.2015.07.050","article-title":"Evaluation of a 36 gy elective node irradiation dose in anal cancer","volume":"116","author":"L\u00e9pinoy","year":"2015","journal-title":"Radiother Oncol"},{"key":"R24-24-20241021","first-page":"3518","article-title":"Compliance to chemoradiation (CRT) using mitomycin (MMC) or cisplatin (CisP), with or without maintenance 5FU\/CisP chemotherapy (CT) in squamous cell carcinoma of the anus (SCCA) according to radiotherapy (RT) dose, overall treatment time (OTT) and chemotherapy (CT) and their impact on long-term outcome: Results of ACT II","volume":"33","author":"Glynne-Jones","year":"2015","journal-title":"J Clin Orthod"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_212_19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:38:00Z","timestamp":1787067480000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_212_19"}},"subtitle":["Implementation and outcomes"],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":22,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_212_19","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}